NCT00266552 – The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder and Other Disruptive Behavior Disorders In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years Posted on October 20, 2014 by tsuperadmin -
NCT00250354 – The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years Posted on October 20, 2014 by tsuperadmin -
NCT00236470 – Risperidone in the Treatment of Children and Adolescents With Conduct and Other Disruptive Behavior Disorders – an Open Label Follow-up Trial of CR002020 Posted on October 20, 2014 by tsuperadmin -
NCT00236444 – Risperidone in the Prevention of Relapse: a Randomized, Double-blind, Placebo-controlled Trial in Children and Adolescents With Conduct and Other Disruptive Behavior Disorders Posted on October 20, 2014 by tsuperadmin -
NCT00094926 – A Prospective, Randomized, Double-blind, Placebo-controlled Study of the Effectiveness and Safety of RISPERDAL CONSTA Augmentation in Adult Patients With Frequently-relapsing Bipolar Disorder Posted on September 25, 2014 by tsuperadmin -
NCT00132678 – A Randomized, Double-blind, Placebo-controlled Study to Explore the Efficacy and Safety of Risperidone Long-acting Intramuscular Injectable in the Prevention of Mood Episodes in Bipolar 1 Disorder, With Open-label Extension Posted on September 25, 2014 by tsuperadmin -
NCT00076115 – Research on the Effectiveness of Risperidone in Bipolar Disorder in Adolescents and Children (REACH): A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Risperidone for the Treatment of Acute Mania in Bipolar I Disorder Posted on September 25, 2014 by tsuperadmin -
NCT00034749 – The Efficacy and Safety of Risperidone in Adolescents With Schizophrenia: a Comparison of Two Dose Ranges of Risperidone Posted on September 25, 2014 by tsuperadmin -
NCT00391222 – A Randomized, Double Blind, Placebo and Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Risperidone Long-acting Injectable (LAI) for the Prevention of Mood Episodes in the Treatment of Subjects With Bipolar I Disorder Posted on September 25, 2014 by tsuperadmin -